Difficulty: Medium
Average Score: 85%
Testbank
The nurse is preparing to administer famotidine to a client with gastroesophageal reflux disease. Which safety warning should the nurse consider when administering the medication?
Correct answer
A
Rationale
Do not allow the client to take the maximum dose of famotidine for more than 2 weeks without medical consultation. This warning is crucial because prolonged use at high doses can mask underlying conditions and lead to potential complications, necessitating medical evaluation to ensure safe and effective treatment management for gastroesophageal reflux disease.
B: Review client's cardiac status and sodium restrictions. While cardiac status and sodium intake are important considerations in some medications, they are not specifically relevant to famotidine administration for gastroesophageal reflux disease.
C: Do not give other oral drugs within 1 to 2 hours of administering the medication. Although famotidine can affect the absorption of other drugs, this timing is not a primary safety concern associated with its use in this context.
D: Be aware that long-term use may be associated with bone fractures. While there is some evidence linking long-term use of certain acid-reducing medications to bone fractures, this does not directly apply to the immediate safety concerns when administering famotidine for gastroesophageal reflux disease.
B: Review client's cardiac status and sodium restrictions. While cardiac status and sodium intake are important considerations in some medications, they are not specifically relevant to famotidine administration for gastroesophageal reflux disease.
C: Do not give other oral drugs within 1 to 2 hours of administering the medication. Although famotidine can affect the absorption of other drugs, this timing is not a primary safety concern associated with its use in this context.
D: Be aware that long-term use may be associated with bone fractures. While there is some evidence linking long-term use of certain acid-reducing medications to bone fractures, this does not directly apply to the immediate safety concerns when administering famotidine for gastroesophageal reflux disease.